Table 2.
Medium score (and interquartile range) for the Nasal Obstruction Symptom Evaluation Scale (NOSE), the Snore Outcomes Survey (SOS; selected items), the 20-Item Sino-Nasal Outcome Test, German Adapted Version (SNOT-20 GAV), the EQ-5D-5L questionnaire and parameters of disordered breathing and snoring during sleep assessed by the WatchPAT200 at study enrollment (t1) and 90 days after radiofrequency treatment (t3); sample size and significance level of the Wilcoxon signed-rank test
| t 1 | t 3 | N | p (one-tailed) | |
|---|---|---|---|---|
| Mdn (IQR) | Mdn (IQR) | |||
| Nasal Obstruction Symtom Evaluation Scale (NOSE) | 65.00 (20.00) | 30.00 (25.00) | 31 | 0.000 |
| Snore Outcomes Survey (SOS; selected items) | 66.67 (31.25) | 41.67 (29.17) | 27 | 0.000 |
| 20-Item Sino-Nasal Outcome Test, German Adapted Version (SNOT-20 GAV) | ||||
| Total Score (TS) | 30.00 (26.00) | 19.00 (16.00) | 31 | 0.000 |
| Primary Nasal Symptoms (PNS) | 32.00 (28.00) | 20.00 (16.00) | 31 | 0.000 |
| Secondary Rhinogenic Symptoms (SRS) | 20.00 (20.00) | 10.00 (10.00) | 31 | 0.000 |
| Generic Quality of Life (GQL) | 28.89 (28.89) | 20.00 (24.44) | 31 | 0.003 |
| EuroQoL group questionnaire for generic quality of life (EQ-5D-5L) | ||||
| Visual Analog Scale (VAS) | 80.00 (22.50) | 80.00 (21.00) | 29 | 0.030 |
| Sum Score (SS) | 95.00 (20.00) | 95.00 (10.00) | 31 | 0.033 |
| WatchPAT200 | ||||
| Apnea–Hypopnea Index (AHI) | 8.21 (10.39) | 8.15 (16.96) | 31 | 0.197 |
| Mean snoring intensity (dB) | 41.00 (1.00) | 41.00 (1.00) | 30 | 0.497 |
| Percent of sleeping time spent with a snoring intensity > 45 dB | 2.25 (5.18) | 2.45 (5.13) | 30 | 0.237 |
Bold—Significance level p: probability that the difference between the data collected at the measurement time points mentioned occured randomly or by chance, but is instead attributed to the low energy radiofrequency remodeling treatment (probabilty of error α)
Statistical comparisons by Wilcoxon signed-rank test; p significance level (one-tailed) concerning the difference of scores at time points t1 and t3
Mdn median, IQR interquartile range, N number of participants